216 related articles for article (PubMed ID: 27435972)
1. Population Exposure-Response Modeling of Naloxegol in Patients With Noncancer-Related Pain and Opioid-Induced Constipation.
Al-Huniti N; Nielsen JC; Hutmacher MM; Lappalainen J; Cantagallo K; Sostek M
CPT Pharmacometrics Syst Pharmacol; 2016 Jul; 5(7):359-66. PubMed ID: 27435972
[TBL] [Abstract][Full Text] [Related]
2. Population Exposure-Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid-Induced Constipation.
Al-Huniti N; Xu H; Zhou D; Aksenov S; Fox R; Bui KH
CPT Pharmacometrics Syst Pharmacol; 2017 Oct; 6(10):705-711. PubMed ID: 28782266
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation.
White WB; Kowey P; Diva U; Sostek M; Tummala R
J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):309-317. PubMed ID: 29504415
[TBL] [Abstract][Full Text] [Related]
4. Naloxegol: treatment for opioid-induced constipation in chronic non-cancer pain.
Leonard J; Baker DE
Ann Pharmacother; 2015 Mar; 49(3):360-5. PubMed ID: 25471070
[TBL] [Abstract][Full Text] [Related]
5. Treatment with Naloxegol Versus Placebo: Pain Assessment in Patients with Noncancer Pain and Opioid-Induced Constipation.
Webster L; Diva U; Tummala R; Sostek M
Pain Pract; 2018 Apr; 18(4):505-514. PubMed ID: 28898536
[TBL] [Abstract][Full Text] [Related]
6. A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation.
Webster L; Tummala R; Diva U; Lappalainen J
J Opioid Manag; 2016; 12(6):405-419. PubMed ID: 28059433
[TBL] [Abstract][Full Text] [Related]
7. Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain.
Holder RM; Rhee D
Pharmacotherapy; 2016 Mar; 36(3):287-99. PubMed ID: 26945548
[TBL] [Abstract][Full Text] [Related]
8. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation.
Webster L; Chey WD; Tack J; Lappalainen J; Diva U; Sostek M
Aliment Pharmacol Ther; 2014 Oct; 40(7):771-9. PubMed ID: 25112584
[TBL] [Abstract][Full Text] [Related]
9. Naloxegol for opioid-induced constipation in patients with noncancer pain.
Chey WD; Webster L; Sostek M; Lappalainen J; Barker PN; Tack J
N Engl J Med; 2014 Jun; 370(25):2387-96. PubMed ID: 24896818
[TBL] [Abstract][Full Text] [Related]
10. Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility.
Lawson R; King F; Marsh K; Altincatal A; Cimen A
Adv Ther; 2016 Aug; 33(8):1331-46. PubMed ID: 27342744
[TBL] [Abstract][Full Text] [Related]
11. Naloxegol for the treatment of opioid-induced constipation.
Tack J; Corsetti M
Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):855-61. PubMed ID: 25220391
[TBL] [Abstract][Full Text] [Related]
12. Naloxegol: a review of its use in patients with opioid-induced constipation.
Garnock-Jones KP
Drugs; 2015 Mar; 75(4):419-25. PubMed ID: 25666542
[TBL] [Abstract][Full Text] [Related]
13. Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation.
Corsetti M; Tack J
Drugs Today (Barc); 2015 Aug; 51(8):479-89. PubMed ID: 26380386
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of naloxegol for opioid-induced constipation assessed by specific opioid medication, opioid dose, and duration of opioid use.
Nalamachu S; Gudin J; Datto C; Coyne K; Poon JL; Hu Y
J Opioid Manag; 2018; 14(3):211-221. PubMed ID: 30044486
[TBL] [Abstract][Full Text] [Related]
15. Naloxegol , a new drug for the treatment of opioid-induced constipation.
Corsetti M; Tack J
Expert Opin Pharmacother; 2015 Feb; 16(3):399-406. PubMed ID: 25496063
[TBL] [Abstract][Full Text] [Related]
16. Naloxegol: A Novel Therapy in the Management of Opioid-Induced Constipation.
Jones R; Prommer E; Backstedt D
Am J Hosp Palliat Care; 2016 Nov; 33(9):875-880. PubMed ID: 26150678
[TBL] [Abstract][Full Text] [Related]
17. Naloxegol: A Review of Clinical Trials and Applications to Practice.
Dume R; Shuman M
Orthop Nurs; 2019; 38(3):209-211. PubMed ID: 31124873
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UK.
Lawson R; Ryan J; King F; Goh JW; Tichy E; Marsh K
Pharmacoeconomics; 2017 Feb; 35(2):225-235. PubMed ID: 27663572
[TBL] [Abstract][Full Text] [Related]
19. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation.
Webster L; Dhar S; Eldon M; Masuoka L; Lappalainen J; Sostek M
Pain; 2013 Sep; 154(9):1542-1550. PubMed ID: 23726675
[TBL] [Abstract][Full Text] [Related]
20. Evidence Based Review of Pharmacotherapy for Opioid-Induced Constipation in Noncancer Pain.
Murphy JA; Sheridan EA
Ann Pharmacother; 2018 Apr; 52(4):370-379. PubMed ID: 29092627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
